Matinas biopharma to feature mat2203 in a pipeline presentation at idweek

Bedminster, n.j., sept. 27, 2023 (globe newswire) -- matinas biopharma (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its proprietary lipid nanocrystal (lnc) platform technology, announces that mat2203, its oral lnc formulation of amphotericin b (amb), will be featured in an oral company pipeline presentation at idweek, being held october 11-15 at the boston convention and exhibition center.
MTNB Ratings Summary
MTNB Quant Ranking